Strategic Partnership Presagen and Qubist have merged to form Qubigen, combining federated AI and AI-driven drug design capabilities. This signals a unified platform approach that could enhance precision drug discovery offerings for pharma, biotechs, and contract research organizations seeking integrated AI solutions.

Tailored AI Models Qubigen is actively developing project-specific AI models to generate actionable insights from client data. This presents a sales opening to target mid to late-stage biotech and pharma clients requiring customized AI workflows, data integration, and rapid POC deployments.

Clinical Collaboration Recent partnerships with Dana-Farber Cancer Institute for kidney cancer research highlight the company’s access to prestigious research networks. Use this to position Qubigen as a conduit for advanced oncology AI research collaborations and potential early-access programs.

Drug Discovery Partnerships Collaborations with Viva Biotech and participation in major biotech events (BIO, JPM Week) indicate active engagement across AI-driven drug discovery ecosystems. This creates opportunities to pursue co-development deals, data-sharing arrangements, and joint venture pilots with CROs, biotech incubators, and life sciences investors.

Growth and Exposure Revenue is under one million with a six-figure funding round, signaling a high-growth, venture-backed company open to strategic customers and channel partnerships. Target larger pharma players and enablement partners seeking scalable federated AI and drug design capabilities integrated into existing workflows.